StockData

Ascentage Pharma Group International vs Ultragenyx Pharmaceutical

AAPG and RARE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AAPG and RARE compare

Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (17.5% versus −41.5% for Ascentage Pharma Group International).

Ultragenyx Pharmaceutical keeps more of each dollar of sales as profit, with a net margin of −81.7% compared with −216% at Ascentage Pharma Group International.

Ultragenyx Pharmaceutical scores higher on the StockData Score (9 against 3 for Ascentage Pharma Group International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAAPGRARE
Size and price
Market cap–$1.6B
Share price$13.14$16.70
Change, 1 year−61.7%−49.5%
Change, 5 years–−78.2%
Beta (5Y)1.432.12
Employees7671,371
StockData Score
Total score39 (better)
Valuation score01 (better)
Growth score12 (better)
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S–2.3×
FCF yield–−29.7%
Growth
Revenue growth (TTM)−41.5%17.5% (better)
Revenue growth, 5Y average–19.9%
Profitability
Gross margin91.5%–
Operating margin–−73.6%
Net margin−216%−81.7% (better)
FCF margin−209%−68.2% (better)
Return on equity−156%–
Financial health
Debt / equity1.50–
Current ratio1.79 (better)1.73
Altman Z-score–−5.26
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.00%108%
Held by insiders13.0%4.0%
Insider net buying, 12 months–−$3.8M
Short interest, % of float–25.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.